Subhasree Nag

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/925136/publications.pdf

Version: 2024-02-01

21	1,622	567281 15	713466 21
papers	citations	h-index	g-index

21	21	21	2882
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exposure to an Environmental Mixture of Polycyclic Aromatic Hydrocarbons Induces Hepatic Cytochrome P450 Enzymes in Mice. Chemical Research in Toxicology, 2021, 34, 2145-2156.	3.3	10
2	In vitro metabolism of benzo[a]pyrene-7,8-dihydrodiol and dibenzo[def,p]chrysene-11,12 diol in rodent and human hepatic microsomes. Toxicology Letters, 2017, 269, 23-32.	0.8	17
3	Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models. Methods in Molecular Biology, 2016, 1406, 271-287.	0.9	3
4	Development and validation of a rapid HPLC method for quantitation of SPâ€141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomedical Chromatography, 2015, 29, 654-663.	1.7	12
5	Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Medicinal Research Reviews, 2015, 35, 1220-1267.	10.5	93
6	Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chinese Journal of Natural Medicines, 2015, 13, 554-560.	1.3	2
7	Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications. Medicinal Research Reviews, 2015, 35, 225-285.	10.5	165
8	Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization,in vitroandin vivoanti-prostate cancer activity, and mechanisms of action. Oncotarget, 2015, 6, 21379-21394.	1.8	57
9	Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy. Current Medicinal Chemistry, 2014, 22, 264-289.	2.4	178
10	The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nature Communications, 2014, 5, 5086.	12.8	70
11	A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 969, 235-240.	2.3	6
12	NFAT as cancer target: Mission possible?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 297-311.	7.4	90
13	RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo. Oncotarget, 2014, 5, 11604-11619.	1.8	46
14	Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?. Current Medicinal Chemistry, 2014, 21, 553-574.	2.4	110
15	Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula linearifolia Turcz.. European Journal of Medicinal Chemistry, 2013, 68, 473-481.	5.5	41
16	miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents. Current Cancer Drug Targets, 2013, 13, 519-541.	1.6	33
17	The MDM2-p53 pathway revisited. Journal of Biomedical Research, 2013, 27, 254.	1.6	279
18	Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents. Current Cancer Drug Targets, 2013, 13, 596-609.	1.6	9

#	Article	IF	Citations
19	Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action. Current Medicinal Chemistry, 2012, 19, 5705-5725.	2.4	56
20	Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2. PLoS ONE, 2012, 7, e41586.	2.5	73
21	Ginsenosides as anticancer agents: In vitro and in vivo activities, structureâ€“activity relationships, and molecular mechanisms of action. Frontiers in Pharmacology, 2012, 3, 25.	3.5	272